A surgeon in Shanghai moves a pair of master controls. Three thousand kilometres away, a four-armed machine mirrors the motion and removes a patient's prostate. No one flew across the border. For MicroPort MedBot's Toumai (图迈) surgical robot, that is no longer science fiction: the company says its tele-robotic variant has already completed nearly 500 remote procedures across more than 100 countries — but the more interesting story is what it takes for a Chinese surgical robot to be allowed to do this at all.
For the patient on the table in Bangkok, the value is not the robot's four arms but the hands that move them. A rural or under-served hospital can, in principle, borrow the judgement of a surgeon who has done the procedure hundreds of times, without the patient boarding a plane or the specialist leaving home. The operation still happens locally — the anaesthesia, the nursing team, the recovery bed, the emergency backup — but the scarcest input, specialist skill, is delivered over a wire. That reframes the machine: it is less a replacement for a surgeon than a very long, very precise extension cord for one.
From import substitute to export candidate
For two decades, the dominant name in robotic surgery was Intuitive Surgical's da Vinci system, an imported standard in Chinese tertiary hospitals. Toumai, built by Shanghai MicroPort MedBot (Group) Co., a subsidiary of MicroPort Scientific (stock code 00853.HK) and itself listed in Hong Kong (02252.HK), was engineered as a domestic alternative. Development began in 2014, the company was established in 2015, and China's NMPA approved the four-arm laparoscopic system in October 2021.
The machine is a teleoperation platform: a seated surgeon controls articulated arms with seven degrees of freedom, views a glasses-free 3D field, and — uniquely among major platforms — receives proprietary force-feedback, so the operator can feel tissue resistance through the instruments.
The certification that actually matters
What changed the international picture was regulation, not a new motor. Toumai received EU CE certification under the Medical Device Regulation (MDR) for its core laparoscopic indications — urology, general surgery, thoracic surgery, and gynecology — in May 2024. The bigger step came in May 2025, when MicroPort's Toumai Tele-Robotic Surgical System became, by the company's account, the world's first commercially approved tele-surgery platform, having already completed nearly 500 remote procedures across more than 100 countries. That approval is the legal door that lets a surgeon in one country operate on a patient in another under the relevant framework.
Regulatory approvals, however, vary by market. The system is not cleared by the U.S. FDA for these uses, and approvals differ country by country. A robot that is legal in Brussels may be unapproved in Boston.
How far it has actually reached
By the end of 2025, MicroPort MedBot reported the Toumai platform had completed more than 15,000 clinical procedures globally, with cumulative commercial orders exceeding 160 units and installations in nearly 40 countries and regions. The tele-robotic variant alone had, by the company's account, completed nearly 500 remote procedures across more than 100 countries. Those are company-reported figures and should be read as such.
The price argument
A recurring claim is cost. Public tender results cited by the company put a Toumai system at roughly RMB 13 million (about US$1.8 million, roughly HK$14 million), against RMB 18–20 million (about US$2.5–2.8 million, roughly HK$19.6–21.8 million) for a da Vinci system in China. The gap is meaningful for hospitals weighing capital budgets, though total cost of ownership includes service, training, and instruments.
Why remote surgery is the real bet
Telesurgery addresses a stubborn problem: specialist surgeons are concentrated in big cities and rich countries. A robot that can be driven from afar could let a centre of excellence serve peripheral hospitals, support surgical education, and extend expertise across borders. The force-feedback that lets the operator feel tissue resistance matters precisely because the surgeon cannot see or touch the field directly — it restores a caution a local operator would have by instinct, narrowing the gap between remote and in-room control. MicroPort has demonstrated procedures over 5G, fibre, and even satellite links. The tele-robotic platform's value is exactly this ability to cross jurisdictions — which is why the company stresses the legal door as much as the network: a connection is useless if the corridor is not permitted.
Why it matters
Toumai's story is less about one machine and more about who gets to use scarce surgical skill. If a centre of excellence can extend its operators across borders through regulation and network rather than through relocation, the geography of medical expertise loosens — a patient's odds begin to depend less on their postcode and more on whether a permitted corridor reaches them. The bottleneck, then, is not the robot but the paperwork that lets it cross a line on a map, and that is a problem for legislators as much as for engineers.
Key takeaways
- Toumai is a Chinese-developed four-arm laparoscopic surgical robot (手术机器人) with CE MDR certification in Europe; its tele-robotic variant was approved for remote surgery in 2025.
- It is priced below imported da Vinci systems — roughly RMB 13 million vs RMB 18–20 million — though service and instruments add to lifetime cost.
- Company-reported reach: 15,000+ procedures by 2025, 160+ units ordered and nearly 40 countries installed by end-2025, nearly 500 remote procedures across 100+ countries.
- Telesurgery's value is geographic: extending specialist expertise to hospitals that lack it.
What readers can do now
- If you are a hospital buyer: verify the specific indication and country approval for any robotic system before budgeting — CE and NMPA clearances do not travel. Document your institution's current robotic case logs and the exact indications cleared in your jurisdiction, then confirm a vendor's claimed certification covers the procedures you actually plan to run, rather than the platform in general.
- If you are a patient: ask whether a centre offering robotic surgery has logged meaningful case volume on that exact platform, not just robotic surgery in general. A useful question to bring to a consultation is how many times the specific surgeon and the specific machine have performed your operation together, since familiarity with one system does not transfer automatically to another.
- If you follow medtech: track which systems clear FDA and beyond-EU markets; today's advantage is regulatory, and regulation is the bottleneck. A practical signal to watch is whether cross-border telesurgery gains a repeatable legal template, because the technology has already outrun many of the corridors it needs to cross.
Honest limitations
All deployment and procedure counts are company-reported and were not independently audited for this article. Telesurgery depends on network latency and legal frameworks that differ by corridor; a successful Shanghai–Bangkok case does not imply universal cross-border permission. Force-feedback and 7-DoF specs are vendor-stated. Long-term clinical outcomes and cost-effectiveness versus both manual laparoscopy and da Vinci are not settled by installation numbers alone. The system remains unapproved by the U.S. FDA for these indications.